International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (1963-1970), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Pathogenesis and Management Approaches of Hepatic Encephalopathy (HE)

[1]Wesam Nafea S Alsharari, [2]Majed Fahad K Alsharari, [3]Muath Abdullah S Alshayban, [4]Sami Naji G Almutiri, [5]Mohammed Ayadhah F Alanazi

Abstract: **Hepatic encephalopathy (HE) is a disturbance in the central nerve system (CNS) feature because of hepatic deficiency or portal-systemic shunting. HE creates a spectrum of neurologic symptoms that create in association with different liver diseases. The purpose of this paper was to discuss the Hepatic encephalopathy (HE), in different manners, we intended to review the pathogenesis, and the treatment of HE. A search was conducted through electronic databases; Medline/ PubMed, direct science and Embase, literature search was performed to identify relevant series discussing and reporting data on Hepatic encephalopathy (HE). A PubMed search was conducted using MeSH term "Hepatic Encephalopathy, combined with Pathogenesis and treatment approaches." further search was done on references lists of these selected article to find more relevant articles supporting our review. HE includes a range of neuropsychiatric signs as well as indications amongst patients with liver failing. Serious HE portends poor end result and also is considered a sign for liver transplantation. In patients with cirrhosis as well as portosystemic shunting, HE creates useful impairment and also considerable morbidity. Numerous factors (specifically ammonia) have actually been implicated in its pathogenesis. Treatment is routed at the adjustment of precipitating factors such as blood poisoning, stomach blood loss, medicines, as well as liquid and also electrolyte imbalance. The pillar of pharmacologic administration includes nonabsorbable disaccharides, mainly lactulose, and anti-biotics.**

Keywords: **Hepatic encephalopathy (HE), central nerve system (CNS).**

1. INTRODUCTION

Hepatic encephalopathy (HE) is a disturbance in the central nerve system (CNS) feature because of hepatic deficiency or portal-systemic shunting. HE creates a spectrum of neurologic symptoms that create in association with different liver diseases [(1)].

It is observed in cirrhotic patients as well as those with acute liver failing (ALF) in the lack of various other recognized brain disease, as a result of decompensated liver feature [(2,3)]. 5 years after the medical diagnosis of cirrhosis, there is 26% chance for developing a minimum of one episode of HE [(4)]. HE is likewise a typical trouble after insertion of a transjugular intrahepatic portosystemic shunt (TIPS) [(5,6)]. In spite of the outstanding developments in our understanding of the several pathophysiological devices which are associated with HE, the therapy options stay an unmet clinical demand, accompanied by significantly high death rates. After the first professional indication of HE, the patients' prognosis is really bad; likelihood of five-year survival is 16% to 22%, compared to that of 55% to 70% in cirrhotic patients without HE [(4,7)]. The pathophysiology of chronic HE is evidently multifactorial, with a number of distributing neurotoxins being included. The systemic build-up of ammonia neurotoxic focus appears to be the most popular factor [(8,9)], while the interorgan ammonia and also amino acid metabolic process is of crucial value in the pathogenesis of HE. The language that numerous writers have used for HE is puzzling. Consequently, numerous initiatives have actually been made to reach a consensus, especially for the style of clinical trials [(9,10)]. The most regular liver disease is cirrhosis, normally accompanied by extrahepatic portal-systemic shunts (spontaneous or medical). HE likewise can be seen in acute liver failing, where it makes up the trademark of the disease. In uncommon instances, HE creates in the lack of any indication of parenchyma liver disease and is caused solely by portal-systemic shunting of genetic or surgical beginning [(10)].

The purpose of this paper was to discuss the Hepatic encephalopathy (HE), in different manners, we intended to review the pathogenesis, and the treatment of HE.

2. METHODOLOGY

A search was conducted through electronic databases; Medline/ PubMed, direct science and Embase, literature search was performed to identify relevant series discussing and reporting data on Hepatic encephalopathy (HE). A PubMed search was conducted using MeSH term "Hepatic Encephalopathy, combined with Pathogenesis and treatment approaches." further search was done on references lists of these selected article to find more relevant articles supporting our review.

3. RESULTS

- ***Pathogenesis of Hepatic encephalopathy (HE):***

Different hypotheses have been proposed to explain the adjustments in psychological state that take place in HE. Ideally, such a concept needs to clarify the relation in between liver and neurological abnormalities. Developing such relationships is difficult, in component, since of restrictions in the techniques offered to examine mind function in human beings as well as likewise due to an insufficient knowledge of the neurobiological basis of actions. However, there is a generalized agreement that the validation of a theory ought to discuss the system of activity of a precipitating factor and exactly how certain treatments enhance HE [(10)].

A typical pathogenetic idea is that HE is triggered by substances that under regular situations are effectively metabolized by the liver, instead of a not enough production of substratums that could be crucial for neurologic feature. Under this light, portal-systemic shunting plays a vital duty, as the main effect of this blood circulation disturbance gets on the focus of gut-derived materials that are very gotten rid of by the liver. Researches of cross-perfusion in animals with speculative HE and liver support group in human beings have shown that clearance of harmful materials present in the blood is more crucial to enhance psychological feature than the synthetic ability of the support system [(11)]. In patients with liver disease, these poisonous substances reach the systemic circulation as a result of portal-systemic shunting or lowered hepatic clearance as well as produce negative impacts on mind function. When the hazardous materials are in neural cells, a multitude of neurochemical adjustments happen that influence multiple neurochemical pathways, each affected to a variable level [(12)]. Research studies investigating the pathophysiology of HE have actually traditionally focused on the build-up of numerous toxins in the blood stream and brains of animal versions as well as patients with chronic liver disease and/or portal hypertension. Ammonia has been implicated as a crucial particle in the disease for over 50 years, due to its frequent altitude in patients with cirrhosis and also well-known mobile toxicity [(13,14)]. Nevertheless, proof currently recommends that ammonia is just a single element in a multifactorial disease process (**Figure 1**) [(12)].



Figure 1: Hypothesis of the multifactorial nature of hepatic encephalopathy.

A. Roles of Ammonia & Glutamine in HE:

Excess ammonia in the body has long been believed to emerge from colonic microbial types with urease enzyme task, mostly gram-negative anaerobes, Enterobacteriaceae, Proteus, and Clostridium types [15,16,17]. The bacterial urease could break down urea originated from the blood stream into ammonia as well as co2. Early investigations right into the treatment of HE as a result concentrated on disabling the bacterial urease enzyme by means of immune-mediated devices such as vaccination [18]. While the intestinal fora still seem a substantial resource of ammonia, proof from animal designs of HE shows that microorganisms are not required for the development of hyperammonemia, recommending that alternative resources also contribute in ammonia production [19,20]. Study has shown that enterocytes within the little bowel (and, to a minimal extent, in the colon) additionally produce a big quantity of ammonia via intestinal glutaminase as they metabolize their primary power resource, glutamine, into glutamate and also ammonia [21]. This endogenous resource of ammonia might even eclipse the production of ammonia by fecal for a [22]. Neomycin, an improperly taken in antibiotic utilized in the therapy of HE, appears to likewise have some inherent effect on the activity of intestinal glutaminase and might lower ammonia by several devices [23].

Ammonia is created in various cells from the breakdown of amino acids and also other nitrogenous compounds. Under typical physiological conditions, ammonia gets in the portal blood circulation from the gastrointestinal tract, where it originates from colonic bacteria and also from the deamidation of glutamine in the tiny bowel. Traditionally, absorption was considered as the outcome of passive diffusion; a lot more current research studies show the visibility of specific ammonia carriers [24]. Ammonia is created largely from nitrogenous items in the diet regimen, microbial metabolic rate of urea as well as healthy proteins in the colon, as well as deamination of glutamine in the small intestine by glutaminase [25,26]. Ammonia is also produced by skeletal muscular tissues, although the pattern of these metabolic paths' contribution to HE pathogenesis is not yet extensively established. From the digestive tract, ammonia is as well as gets in the portal flow transformed to urea by the liver; urea is subsequently secreted by the kidneys [9]. Generally, the major root causes of hyperammonemia are presented in (**Table 1**) [27,28].

Table 1: Etiology of hyperammonemia

Urea cycle deficiencies	ALF & CLD*	Fatty acid oxidation defects	Other
Ornithine transcarbamylase deficiency	Viral infections (ALF)	Acyl-CoA de-hydrogenase deficiency	Gastrointestinal bleeding
Carbamoylphosphate synthetase-I deficiency	Toxins (ALF)	Systemic carnitine deficiency	Valproate, 5-FU, Salicylates
N-acetylglutamine synthetase deficiency	Cystic fibrosis (CLD)		Renal Diseases & infections, Reye's syndrome
Argininosuccinic synthetase deficiency	Wilson disease (CLD)		Parenteral hyperalimentation
Argininosuccinic acid lyase deficiency	Biliary atresia (CLD)		Transient hyperammonemia of newborn
Argininase deficiency	A-1 antitrypsin deficiency (CLD)		Surgical creation of urinary diversion

*ALF – Acute Liver Failure; CLD – Chronic Liver Diseases.

Current research studies utilizing sophisticated PET techniques have examined this tenet [29]. Variations in the flow of ammonia across the blood brain obstacle may describe the bad partnership between the level of arterial ammonia and also the level of HE; nevertheless, the relationship between plasma ammonia levels as well as cerebral dysfunction seems to be clear in patients with acute liver failure in which plasma ammonia have a straight connection with the existence of intracranial high blood pressure as well as fatality [30,31] (**Figure 2**). This connection might be related to the induction of brain edema by ammonia or just be a sign of the severity of liver failing. During HE episodes in cirrhosis, ammonia reveals a significant social irregularity.

Most just recently, glutamine has been shown to have an essential function in the brain poisoning caused by ammonia. It has actually long been accepted that the conversion of glutamate to glutamine, militarized by glutamine synthetase, a cytoplasmic enzyme greatly local in astrocytes in brain, represents the major means of cerebral ammonia detoxification. Much of the recently synthesized glutamine is consequently metabolized in mitochondria by phosphate-activated glutaminase, yielding glutamate and also ammonia. In this way, glutamine is moved over from the cytoplasm to mitochondria acting as a service provider of ammonia. It has been recommended that the glutamine-derived ammonia interferes with mitochondrial feature generating extreme production of free radicals as well as induction of the MPT, 2 sensations recognized to produce astrocyte dysfunction, consisting of cell swelling [32]. This theory is sustained by neuroimaging research studies [33] that had actually shown boosted levels of brain glutamine throughout the HE episode that decreased when the episode had been recovered.



Figure 2: Physiopathology of hepatic encephalopathy.

Inflammation as cause of HE:

The growth of HE is partly attributed to inflammation in view of the high occurrence of infections amongst patients with HE, the link in between pens of systemic inflammatory action syndrome (SIRS) and HE, and the organization of SIRS with damage in psychological standing [34,35]. In researches of cultured astrocytes, inflammatory cytokines generated cell swelling [36]. Lipopolysaccharide, a substance located on the microbial cell wall surface, has actually likewise been revealed to improve ammonia-induced modifications in cerebral hemodynamics [37]. In a professional research of patients with cirrhosis, neuropsychological dysfunction located in the presence of hyperammonemia and SIRS improved after resolution of SIRS [38]. Although the specific mechanisms whereby inflammation adds to the growth of HE have not been clarified, opportunities consist of cytokine-mediated adjustments in BBB leaks in the structure, transformed glutamate uptake by astrocytes, as well as modified expression of GABA receptors [38].

- **Treatment of hepatic encephalopathy: (treating underlining cause):**

Therapy of HE contains the complying with 3 objectives: a) Dealing with speeding up factors of hyperammonemia and accumulation of poisonous metabolites, b) Lowering blood and also analytical ammonia levels, and also c) Dealing with the effects of hyperammonemia and build-up of harmful metabolites. One of one of the most important aspects of handling HE is the ability to possibly reverse its development by prompt acknowledgment and treatment of its speeding up factors prior to a decompensated liver feature occurs. Fessel et al. showed that HE is triggered by reversible factors in over 80% of patients [39]. These usual factors that can be reversed include dehydration, irregular bowel movements, methodical infection, hypokalemia, gastrointestinal hemorrhage, protein over-intake, depressants as well as sedatives (**Table 2**). Resolving these consider time has actually been shown to be crucial in successfully dealing with most patients with HE [40].

Prompt treatment of top or lower GI blood loss is necessary. Acute renal failure as a result of dehydration and diuretics' result might precipitate HE with hypokalaemia, hypoglycaemia and also metabolic alkalosis. Intravenous thiamine substitute ought to be quickly started in nutritionally diminished and also alcoholic patients. The evaluation of current digestive tract habits is critical. Appropriate defecation is crucial as well as actions to generate it ought to be taken [41]. Society from all suitable body liquids ought to be gotten. An analysis paracentesis should be executed in all patients with ascites. In patients with hepatic coma, or pending society outcomes, a brief course of empirical anti-biotics must be considered [40].

The use of psychoactive drugs such as benzodiazepines and also narcotics need to be examined as well as terminated if possible. The toxicology of urine might be additionally essential. Any kind of problem recommending the development of encephalopathy should cause complete discontinuation of chlordiazepoxide and also various other sedatives, or in a limitation to minimal possible doses in drowsy cirrhotic patients that go to risk of delirium tremens [42]. The opportunity of focal neurological injury must be excluded by a cautious background as well as neurological evaluation. In case of any kind of doubt, CT mind imaging need to be executed. EEG evaluation will certainly leave out seizure task, or might confirm the existence of typical slow-moving, triphasic waveforms in the frontal lobes, which are related to HE [41].

Table 2: Factors that contributing on cause of hepatic encephalopathy.

Increased nitrogen load	Electrolyte disorders	Drugs	Other
Gastrointestinal bleeding	Hyponatremia	Narcotics, tranquilizers, sedatives (Central nervous system acting drugs)	Infections (spontaneous bacterial peritonitis, urinary tract, skin, or pulmonary)
Excessive dietary protein	Hypokalemia		Surgery
Azotemia	Metabolic alkalosis/acidosis		Superimposed liver injury (acute hepatitis, drug-induced liver injury)
Constipation	Hypoxia		Progressive liver disease
	Hypovolemia		TIPS
	Dehydration		Renal failure
			Urinary obstruction
			Hepatocellular carcinoma
			Terminal liver disease

Dietary restriction to Lower ammonia levels:

It has been demonstrated that nutritional protein restriction in cirrhotic patients does not ameliorate or turn around the program of HE [43]. As a result, an everyday protein consumption of 1 - 1.5 g/kg of body weight can be securely supervised to a patient with HE, as a favorable nitrogen equilibrium is needed to advertise liver regrowth and also increase capability of skeletal muscle mass to eliminate ammonia in the form of glutamine [44]. Nevertheless, it has actually been verified that the source of the protein consumption might be of relevance in controlling HE, with vegetable healthy proteins being superior to animal-derived ones [45], although the hypothesis that branched -chain amino acids (BCAAs) can boost HE has cannot be shown. On the other hand, a high fiber intake diet seems to ameliorate HE by enhancing the food transportation price via the gastroenteric system and for that reason decreasing the absorption of ammonia right into the mesenteric blood supply [46,47].

Medicinal choice for treatment of HE:

Lactulose (beta-galactosidofructose):

Nonabsorbable disaccharides are taken into consideration the criterion of look after hepatic encephalopathy. These products consist of lactulose and also lactitol (lactitol is not available in the United States). The proof to sustain or shoot down the use of these representatives alone in the therapy of hepatic encephalopathy wants [48,49]. Lactulose, nevertheless, was the only pharmacologic agent available in the United States for the therapy of hepatic encephalopathy for years. [50]. The medicine works in patients with cirrhosis who have minimal hepatic encephalopathy (MHE) [51,52]. An analysis of Cochrane Hepato-Biliary Group information showed efficiency of lactulose over sugar pill, however revealed no benefit in survival [48]. Lactulose has been revealed to enhance cognitive feature and health-related quality of life in patients with MHE [53]. However, it is challenging to objectively evaluate improvement in lifestyle in patients with MHE. A current research found that absence of response to lactulose treatment in cirrhotic patients with MHE was attributed to reduced

serum salt levels as well as high venous ammonia levels [54]. 10 Lactulose is metabolized into lactic and acetic acids, which results in acidification of the stomach lumen. Intestinal acidification inevitably hinders the manufacturing of ammonia by coliform germs. Lactulose likewise serves as a cleansing. The normal dose of lactulose is 30 ml 2- 4 times/day, gotten used to achieve 2 to four soft stools/day [50]. It is hard to follow this routine as a result of the needed dosage changes, making conformity an issue. Inadequate conformity is a recognized restriction of lactulose therapy.



Figure 3: Non-absorbable disaccharides reduce the production and absorption of ammonia.

4. CONCLUSION

HE includes a range of neuropsychiatric signs as well as indications amongst patients with liver failing. Serious HE portends poor end result and also is considered a sign for liver transplantation. In patients with cirrhosis as well as portosystemic shunting, HE creates useful impairment and also considerable morbidity. Numerous factors (specifically ammonia) have actually been implicated in its pathogenesis. Treatment is routed at the adjustment of precipitating factors such as blood poisoning, stomach blood loss, medicines, as well as liquid and also electrolyte imbalance. The pillar of pharmacologic administration includes nonabsorbable disaccharides, mainly lactulose, and anti-biotics

REFERENCES

[1] Adams and J. M. Foley, "The neurological disorder associated with liver disease," Association for Research in Nervous and Mental, vol. 32, pp. 198–237, 1953.

[2] Scherlock S, Dooley J. Hepatic encephalopathy Diseases of the Liver and Biliary System. Oxford: Blackwell Scientific; 1993. pp. 86–101.

[3] Zieve L. Hepatic encephalopathy Disease of the Liver. Philadelphia, Pennsylvania: Lippincott; 1987. pp. 925–48.

[4] Gines P, Quintero E, Arroyo V, et al. Compensated Cirrhosis: natural history and prognostic factors. Hepatology. 1987;7:122–28.

[5] Hazell AS, Butterworth RF. Hepatic encephalopathy: An update of pathophysiologic mechanisms. Proc Soc Exp Biol Med. 1999;222:99–112.

[6] Pomier LG. TIPS and hepatic encephalopathy. Semin Liver Dis. 1996;16:315–20.

[7] Rink CH, Haeting J, Nilius R. Prognosis assessment in patients with liver cirrhosis. Hepatogastroenterology. 1990;37(II):A86, 514.

[8] Butterworth R. Alterations of neurotransmitter-related gene expression in human and experimental portal systemic encephalopathy. Metab Brain Dis. 1998;13:337–49.

[9] Butterworth R. Complications of cirrhosis III. Hepatic encephalopathy. J Hepatol. 2000;32(1):171–80.

[10] Häussinger and F. Schliess, "Pathogenetic mechanisms of hepatic encephalopathy," *Gut*, vol. 57, no. 8, pp. 1156–1165, 2008.

[11] Roche Sicot, C. Sicot, and M. Peignoux, "Acute hepatic encephalopathy in the rat: the effect of cross circulation," Clinical Science and Molecular Medicine, vol. 47, no. 6, pp. 609–615, 1974.

[12] Butterworth, "Altered glial-neuronal crosstalk: cornerstone in the pathogenesis of hepatic encephalopathy," Neurochemistry International, vol. 57, no. 4, pp. 383–388, 2010.

[13] Phear EA, Sherlock S, Summerskill WH. Blood-ammonium levels in liver disease and hepatic coma. Lancet. 1955;268:836–840.

[14] Butterworth RF, Giguère JF, Michaud J, Lavoie J, Layrargues G P. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol. 1987;6:1–12.

[15] Vince AJ, Burridge SM. Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J Med Microbiol. 1980;13:177–191.

[16] Floch MH, Katz J, Conn HO. Qualitative and quantitative relationships of the fecal fora in cirrhotic patients with portal systemic encephalopathy and following portacaval anastomosis. Gastroenterology. 1970;59:70–75.

[17] Wolpert E, Phillips S F, Summerskill WH. Ammonia production in the human colon. Effects of cleansing, neomycin and acetohydroxamic acid. N Engl J Med. 1970;283:159–164.

[18] LeVeen HH, LeVeen EG, LeVeen RF. Awakenings to the pathogenicity of urease and the requirement for continuous long term therapy. Biomed Pharmacother. 1994;48:157–166.

[19] Weber FL, Jr, Veach GL. The importance of the small intestine in gut ammonium production in the fasting dog. Gastroenterology. 1979;77:235–240.

[20] Nance FC, Batson RC, Kline DG. Ammonia production in germ-free Eck fistula dogs. Surgery. 1971;70:169–174.

[21] Plauth M, Roske AE, Romaniuk P, Roth E, Ziebig R, Lochs H. Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration. Gut. 2000;46:849–855.

[22] Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology. 2002;36:1163–1171.

[23] Hawkins RA, Jessy J, Mans AM, Chedid A, DeJoseph MR. Neomycin reduces the intestinal production of ammonia from glutamine. Adv Exp Med Biol. 1994;368:125–134.

[24] V. Felipo, A. Urios, E. Montesinos et al., "Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy," *Metabolic Brain Disease*, vol. 27, no. 1, pp. 51–58, 2012.

[25] Gerber T, Schomerus H. Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management. Drugs. 2000;60:1353–70.

[26] Sundaram V, Shaikh OS. Hepatic Encephalopathy: Pathophysiology and Emerging Therapies. Med Clin North Am. 2009;93:819–36.

[27] Ahlam M, Joe TRC. Ornithine transcarboylase deficiency presenting with acute liver failure. JIMD Short Reprt 006 2006. Online.

[28] Hawkes ND, Thomas GA, Jurewicz A, et al. Non-hepatic hyperammonemia: an important, potentially reversible cause of encephalopathy. Postgrad Med J. 2001;77:717–22.

[29] Haussinger, "Hepatocyte heterogeneity in glutamine and ammonia metabolism and the role of an intercellular glutamine cycle during ureogenesis in perfused rat liver," *European Journal of Biochemistry*, vol. 133, no. 2, pp. 269–275, 1983.

[30] Norenberg and A. Martinez-Hernandez, "Fine structural localization of glutamine synthetase in astrocytes of rat brain," *Brain Research*, vol. 161, no. 2, pp. 303–310, 1979.

[31] Blei, S. Olafsson, G. Therrien, and R. F. Butterworth, "Ammonia-induced brain edema and intracranial hypertension in rats after portacaval anastomosis," *Hepatology*, vol. 19, no. 6, pp. 1437–1444, 1994.

[32] Brusilow, R. C. Koehler, R. J. Traystman, and A. J. L. Cooper, "Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy," *Neurotherapeutics*, vol. 7, no. 4, pp. 452–470, 2010.

[33] Skowrońska and J. Albrecht, "Alterations of blood brain barrier function in hyperammonemia: an overview," *Neurotoxicity Research*, vol. 21, no. 2, pp. 236–244, 2012.

[34] Rolando N, Wade J, Davalos M, et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000;32:734–9.

[35] Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003;125:755–64.

[36] Haussinger D, Schliess F. Astrocyte swelling and protein tyrosine nitration in hepatic encephalopathy. Neurochem Int 2005;47:64–70.

[37] Pedersen HR, Ring-Larsen H, Olsen NV, et al. Hyperammonemia acts synergistically with lipopolysaccharide in inducing changes in cerebral hemodynamics in rats anaesthetised with pentobarbital. J Hepatol 2007;47:245–52.

[38] Shawcross DL, Davies NA, Williams R, et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004;40:247–54.

[39] Fessel JN, Conn HO. An analysis of the causes and prevention of hepatic coma. Gastroenterology. 1972;62:191.

[40] Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med. 1993;2:414–16.

[41] Cash WJ, McConville P, McDermott E, et al. Current concepts in the assessment and treatment of Hepatic Encephalopathy. Q J Med. 2010;103:9–16.

[42] Ahboucha S, Butterworth RF. The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy. Neurochem Int. 2008;52:575–87.

[43] Córdoba J, López-Hellín J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: Results of a randomized study. J Hepatol. 2004;41:38–43.

[44] Swart GR, van den Berg JW, van Vuure JK, et al. Minimum protein requirements in liver cirrhosis determined by nitrogen balance measurements at three levels of protein intake. Clin Nutri. 1989;8:329–36.

[45] Bianchi GP, Marchesini G, Fabbri A, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomised cross-over comparison. J Intern Med. 1993;223:385–92.

[46] Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337:473–79.

[47] Tozun N. Influence of the metabolic complications of liver cirrhosis on dietary intake. Med Sci Monit. 2000;6(6):RA1223–26.

[48] Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. BMJ 2004;328:1046–51.

[49] Blei AT, Córdoba J. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968–76.

[50] Munoz SJ. Hepatic encephalopathy. Med Clin N Am 2008;92:795–812

[51] Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000;45: 1549–52.

[52] Horsmans Y, Solbreux PM, Daenens C, Desager JP, Geubel AP. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 1997;11:165–70.

[53] Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and healthrelated quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549–59.

[54] Sharma P, Sharma BC, Sarin SK. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis. Liver Int 2009;29:1365–71.